HyTest’s patent portfolio consists of several patents relating to diagnostics of cardiovascular diseases. For further information and inquiries regarding patent licensing, please contact us by writing to: email@example.com.
The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.
This invention relates to clinical diagnostics and more particularly to the diagnostics and therapy follow-up of heart muscle necrosis. The invention concerns with a new approach to monitor the condition of heart by leakage of two proteins, troponin I and C, from necrotic heart muscle.
This invention relates to BNP antigen, and particularly to use of a new stable from of said antigen as a standard or calibrator in immunoassays measuring BNP immunoreactivity.
This invention relates to immunoassays, and provides an immunoassay method for detection of unstable antigens. The method is specifically suitable for detection of BNP, proBNP and fragments thereof.
This invention describes a method for diagnosing of cardiovascular diseases, which comprises detection of IGFBP-4 (insulin- like growth factor binding protein-4) fragments in patients’ blood. It provides antibodies as well as epitopes for antibodies, specific to proteolytic fragments (both N- and C-terminal) of IGFBP-4 originated from IGFBP-4 molecule after its cleavage by specific protease PAPP-A. Antibodies could be used for development of immunoassay methods for quantitative or qualitative detection of IGFBP-4 fragments in human blood.